English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.022099% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.000123% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | EUR | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Spain | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 8.03 |
| Open | 8.2 |
| 1-Year Change | -10.09% |
| Day's Range | 8.2 - 8.38 |
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
BRIEF: For the fiscal year ended 31 December 2021, Grifols SA revenues decreased 8% to EUR4.93B. Net income before extraordinary items decreased 72% to EUR182.8M. Revenues reflect Bioscience segment decrease of 10% to EUR3.81B, United States/Canada segment decrease of 12% to EUR3.15B, Rest of the World segment decrease of 4% to EUR872.1M. Net income also reflects Selling/General/Admin. Expense - Balanci increase of 11% to EUR567.3M (expense).
12/11, 10% Stock dividend. 12/2011, Scrip Issue, 1 new share for every 10 shares held @ EUR0.1 (Factor: 1.1), 12/2012, Scrip Issue, 1 new B shares for every 20 B shares held (Factor: 1.05). 1/2016, 2-for-1 stock split (Factor: 2).
